User started using minoxidil twice daily and microneedling every five days about 8-9 weeks ago. The post is about their progress with these treatments.
Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. Concerns were raised about delays in product presentations and business strategies.
The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.
Microneedling can cause skin shedding and inflammation, with some users adjusting needle size or frequency to reduce these effects. Some users combine microneedling with treatments like minoxidil, while others prefer smaller needles or alternative treatments like dutasteride.
A user who has been using the "Big 3" hair loss treatments (ketoconazole, minoxidil and finasteride) for 2-3 months and is hoping to see positive results. The other user commented that they look like a hyper responder and asked if they were using oral or topical fin/min.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
The conversation is about improving scalp appearance by regaining adipose tissue and making the skin look better using scalp massages and a moisturizer with hyaluronic acid, ceramides, and urea. The user is not trying to regrow hair but wants to improve the scalp's thickness and appearance.
User noticed receding temples, used minoxidil and microneedling with positive results. Added saw palmetto and eucapil, experienced shedding and thinner hairline, but no side effects.
A user who initially had positive results with oral finasteride, topical minoxidil, and microneedling for hair loss, but experienced side effects like fog and depression. After stopping and losing progress, they restarted with topical treatments and microneedling, reporting good results and no side effects.
Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
Applying lavender essential oil before microneedling is discouraged due to potential skin irritation. Microneedling followed by oil application, like black castor oil, is more common and may benefit hair and scalp health.
A 46-year-old male shared his 3-week progress using HIMS serum with Finasteride 0.3% and Minoxidil 6%, showing improvement without noticeable shedding. His routine includes vitamins, a healthy diet, and specific hair care practices like microneedling and using caffeine solution.
People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.
The conversation is about two new videos on exosomes, focusing on how they work and a Q&A session about their use. Specific treatments for hair loss are not discussed.
The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.
A user reports positive results after 6 months using a topical finasteride/minoxidil spray and a hair and nail health vitamin for hair loss. They were initially skeptical but now are satisfied with their hair appearing to age gracefully.
A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.
A 47-year-old male experienced significant hair regrowth over six months using 1mg oral finasteride, 5mg oral minoxidil, and 1ml 5% topical minoxidil, along with weekly derm stamping. He reported no major side effects, improved prostate health, and increased vascularity, with hair texture changes and minor nasal congestion.
The conversation discusses hair loss treatments, including minoxidil, finasteride, biotin, folic acid, zinc, micro-needling, niacin, and cipaxil, with the user preparing for a hair transplant. The user experiences side effects with topical finasteride and is hesitant to try oral dutasteride.
Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.
A 50-year-old user shares progress on hair loss treatment after 4 months using finasteride and minoxidil, along with 2 laser sessions with exosomes. The user hopes to restore the crown and mid-scalp areas.
The conversation discusses the effectiveness of finasteride and microneedling for treating hair loss. The linked article is seen as an advertisement for these treatments.
The conversation is about a person's nearly 5-month progress using finasteride, minoxidil, some vitamins, and occasional microneedling to treat hair loss, with noticeable improvement in hair growth. They also mention not using creatine or performance-enhancing drugs.
The user is happy with hair regrowth progress using monthly microinjections of minoxidil and dutasteride, along with daily oral intake of these treatments. The treatment costs $200 per session, and the user plans to continue for a year before stopping.
Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.